MA46230A - Mutations de protéine d'enveloppe du vih stabilisant la forme trimère - Google Patents
Mutations de protéine d'enveloppe du vih stabilisant la forme trimèreInfo
- Publication number
- MA46230A MA46230A MA046230A MA46230A MA46230A MA 46230 A MA46230 A MA 46230A MA 046230 A MA046230 A MA 046230A MA 46230 A MA46230 A MA 46230A MA 46230 A MA46230 A MA 46230A
- Authority
- MA
- Morocco
- Prior art keywords
- hiv
- envelope protein
- envelope proteins
- hiv envelope
- trimer
- Prior art date
Links
- 101710091045 Envelope protein Proteins 0.000 title abstract 9
- 101710188315 Protein X Proteins 0.000 title abstract 9
- 102100021696 Syncytin-1 Human genes 0.000 title abstract 9
- 239000013638 trimer Substances 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title abstract 2
- 230000000087 stabilizing effect Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des protéines d'enveloppe du virus de l'immunodéficience humaine (vih) présentant des mutations qui stabilisent la forme trimère de la protéine d'enveloppe. Les protéines d'enveloppe du vih présentent certaines substitutions d'acides aminés à des positions particulières dans la séquence de protéine d'enveloppe. Les protéines d'enveloppe du vih décrites dans la description présentent un pourcentage amélioré de formation de trimère et/ou un rendement amélioré en trimère telles que comparées à une protéine d'enveloppe du vih qui ne possède pas l'une ou plusieurs des substitutions d'acides aminés indiquées. La présente invention concerne également des molécules d'acide nucléique et des vecteurs codant pour les protéines d'enveloppe du vih, ainsi que des compositions contenant les protéines d'enveloppe du vih, l'acide nucléique, et les vecteurs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16188866 | 2016-09-15 | ||
PCT/EP2017/073141 WO2018050747A1 (fr) | 2016-09-15 | 2017-09-14 | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère |
Publications (2)
Publication Number | Publication Date |
---|---|
MA46230A true MA46230A (fr) | 2019-07-24 |
MA46230B1 MA46230B1 (fr) | 2020-10-28 |
Family
ID=57017955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA46230A MA46230B1 (fr) | 2016-09-15 | 2017-09-14 | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère |
Country Status (30)
Country | Link |
---|---|
US (3) | US10793607B2 (fr) |
EP (2) | EP3512543B1 (fr) |
JP (2) | JP7178344B2 (fr) |
KR (1) | KR102513146B1 (fr) |
CN (1) | CN109689091A (fr) |
AR (1) | AR109528A1 (fr) |
AU (2) | AU2017327672B2 (fr) |
BR (1) | BR112019004593A2 (fr) |
CA (1) | CA3036959A1 (fr) |
CY (1) | CY1124518T1 (fr) |
DK (1) | DK3512543T3 (fr) |
EA (1) | EA201990715A1 (fr) |
ES (1) | ES2824525T3 (fr) |
HR (1) | HRP20201458T1 (fr) |
HU (1) | HUE052008T2 (fr) |
IL (2) | IL294832A (fr) |
LT (1) | LT3512543T (fr) |
MA (1) | MA46230B1 (fr) |
MD (1) | MD3512543T2 (fr) |
MX (1) | MX2019002938A (fr) |
MY (1) | MY190534A (fr) |
PH (1) | PH12019500280A1 (fr) |
PL (1) | PL3512543T3 (fr) |
PT (1) | PT3512543T (fr) |
RS (1) | RS60919B1 (fr) |
SG (2) | SG11201901206SA (fr) |
SI (1) | SI3512543T1 (fr) |
TW (1) | TWI742158B (fr) |
WO (1) | WO2018050747A1 (fr) |
ZA (1) | ZA201901597B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6510149B2 (ja) | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
CA3016352A1 (fr) | 2016-03-03 | 2017-09-08 | Duke University | Compositions et procedes pour induire des anticorps du vih-1 |
MX2018013455A (es) * | 2016-05-02 | 2019-02-28 | Scripps Research Inst | Composiciones y metodos relacionados con inmunogenos de vih-1. |
KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
CA3035759A1 (fr) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral |
BR112019004593A2 (pt) | 2016-09-15 | 2019-07-02 | Janssen Vaccines & Prevention Bv | mutações da proteína do envelope do hiv estabilizando o trímero |
CA3039089A1 (fr) | 2016-10-03 | 2018-04-12 | Duke University | Procedes d'identification d'immunogenes par ciblage de mutations improbables |
MA49397A (fr) | 2017-06-15 | 2020-04-22 | Bavarian Nordic As | Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation |
SG11202000112XA (en) * | 2017-07-19 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
JP2021527077A (ja) | 2018-06-13 | 2021-10-11 | ザ スクリプス リサーチ インスティテュート | 新規構造成分を含有するナノ粒子ワクチン |
EA038287B1 (ru) * | 2018-06-18 | 2021-08-04 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизирующие тример мутации белка оболочки hiv |
EP3860650A4 (fr) * | 2018-10-01 | 2022-06-29 | Duke University | Mutations stabilisant l'enveloppe du vih-1 |
US20220106610A1 (en) * | 2019-01-22 | 2022-04-07 | Bluebird Bio, Inc. | Methods and systems for manufacturing viral vectors |
CN110184298B (zh) * | 2019-05-15 | 2023-05-16 | 武汉璟泓科技股份有限公司 | Hiv突变型表面糖蛋白及其纳米化抗原与制备方法 |
US20220401546A1 (en) * | 2019-11-14 | 2022-12-22 | Emory University | HIV Immunogens, Vaccines, and Methods Related Thereto |
CN114478796A (zh) * | 2020-11-12 | 2022-05-13 | 厦门大学 | 经改造的人免疫缺陷病毒膜蛋白及其应用 |
CN116867517A (zh) | 2021-02-23 | 2023-10-10 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
WO2023156505A1 (fr) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimère stabilisant les mutations de protéines d'enveloppe du vih r304v, n302m et t320l |
WO2023192835A1 (fr) * | 2022-03-27 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ectodomaines de l'enveloppe du vih-1 recouverts d'une base et leur utilisation |
WO2024091921A1 (fr) * | 2022-10-24 | 2024-05-02 | Duke University | Stabilisation d'enveloppes du virus de l'immunodéficience humaine (vih) |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1341245C (fr) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Virus recombinant de la vaccine derive du virus modifie ankara |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
CA2384271A1 (fr) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Trimeres stabilises solubles de glycoproteines |
EP1598425A1 (fr) | 2000-11-23 | 2005-11-23 | Bavarian Nordic A/S | Variant modifié du virus de la vaccine ankara |
CN101397574A (zh) | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
US7901690B2 (en) | 2002-12-03 | 2011-03-08 | University Of Massachusetts | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
EP2363143A3 (fr) | 2003-03-28 | 2012-02-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MVA exprimant des gènes enveloppe, gag et pol du vih |
US20070166784A1 (en) | 2003-09-15 | 2007-07-19 | Barnett Susan W | Combination approaches for generating immune responses |
EP1667714B1 (fr) * | 2003-09-17 | 2018-01-03 | Duke University | Immunogenes consensus/ancestraux |
US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
EP1766097A4 (fr) | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1 |
AU2005274948B2 (en) | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
CN1857345B (zh) * | 2005-05-08 | 2010-09-01 | 谢秀琼 | 一种治疗偏头痛的药物组合物及其制备方法 |
CA2656741A1 (fr) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur |
AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
CA2655934A1 (fr) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Proteines env vih trimeriques solubles stabilisees et leurs utilisations |
WO2008063331A2 (fr) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci |
WO2008140579A2 (fr) | 2006-11-17 | 2008-11-20 | New York University | Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1 |
AU2008223951B2 (en) | 2007-03-02 | 2014-03-27 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
PT3335728T (pt) | 2008-10-10 | 2020-02-19 | Childrens Medical Center | Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada |
DK2358757T3 (da) | 2008-11-18 | 2019-01-02 | Beth Israel Deaconess Medical Ct Inc | Antivirale vacciner med forbedret cellulær immunogenicitet |
WO2010096561A1 (fr) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protéines gag du vih/vis de synthèse et leurs utilisations |
WO2011082087A2 (fr) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Protéines de fusion avec des dps destinées à être utilisées dans des vaccins et des produits de diagnostic |
CA2786333C (fr) | 2010-01-28 | 2018-03-20 | Bavarian Nordic A/S | Mutants du virus de la vaccine comportant les principales deletions genomiques du virus de la vaccine ankara modifiee |
EP2926830B1 (fr) | 2010-08-31 | 2017-08-02 | Theraclone Sciences, Inc. | Anticorps de neutralisation du virus de l'immunodéficience humaine (vih) |
US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
WO2013055908A1 (fr) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | Mini boucle v3 de gp120 du vih-1 et ses utilisations |
WO2014047261A1 (fr) | 2012-09-19 | 2014-03-27 | Beth Israel Deaconess Medical Center, Inc. | Virus associés à l'immunodéficience et l'entéropathie et procédés d'utilisation de ceux-ci |
CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
SG11201505229XA (en) | 2013-01-07 | 2015-08-28 | Beth Israel Hospital | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
WO2014124301A1 (fr) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Nanostructures protéiques à auto-assemblage |
US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
EP3189067B1 (fr) | 2014-09-04 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Protéines de l'enveloppe du vih-1 et leur utilisation |
ES2865150T3 (es) | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
LT3271729T (lt) | 2015-03-18 | 2021-02-25 | Janssen Vaccines & Prevention B.V. | Rekombinantinių raiškos sistemų analizės būdai |
JP6510149B2 (ja) | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
CA3035759A1 (fr) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral |
BR112019004593A2 (pt) | 2016-09-15 | 2019-07-02 | Janssen Vaccines & Prevention Bv | mutações da proteína do envelope do hiv estabilizando o trímero |
SG11202000112XA (en) * | 2017-07-19 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
-
2017
- 2017-09-14 BR BR112019004593A patent/BR112019004593A2/pt unknown
- 2017-09-14 SG SG11201901206SA patent/SG11201901206SA/en unknown
- 2017-09-14 SI SI201730416T patent/SI3512543T1/sl unknown
- 2017-09-14 MA MA46230A patent/MA46230B1/fr unknown
- 2017-09-14 AR ARP170102536A patent/AR109528A1/es unknown
- 2017-09-14 MD MDE20190798T patent/MD3512543T2/ro unknown
- 2017-09-14 WO PCT/EP2017/073141 patent/WO2018050747A1/fr active Search and Examination
- 2017-09-14 HU HUE17769027A patent/HUE052008T2/hu unknown
- 2017-09-14 IL IL294832A patent/IL294832A/en unknown
- 2017-09-14 AU AU2017327672A patent/AU2017327672B2/en active Active
- 2017-09-14 PL PL17769027T patent/PL3512543T3/pl unknown
- 2017-09-14 PT PT177690278T patent/PT3512543T/pt unknown
- 2017-09-14 DK DK17769027.8T patent/DK3512543T3/da active
- 2017-09-14 EA EA201990715A patent/EA201990715A1/ru unknown
- 2017-09-14 US US15/704,651 patent/US10793607B2/en active Active
- 2017-09-14 JP JP2019514316A patent/JP7178344B2/ja active Active
- 2017-09-14 MY MYPI2019001242A patent/MY190534A/en unknown
- 2017-09-14 IL IL265186A patent/IL265186B/en unknown
- 2017-09-14 LT LTEP17769027.8T patent/LT3512543T/lt unknown
- 2017-09-14 KR KR1020197007592A patent/KR102513146B1/ko active IP Right Grant
- 2017-09-14 CA CA3036959A patent/CA3036959A1/fr active Pending
- 2017-09-14 EP EP17769027.8A patent/EP3512543B1/fr active Active
- 2017-09-14 SG SG10202001956UA patent/SG10202001956UA/en unknown
- 2017-09-14 RS RS20201208A patent/RS60919B1/sr unknown
- 2017-09-14 EP EP20179463.3A patent/EP3747463A1/fr active Pending
- 2017-09-14 MX MX2019002938A patent/MX2019002938A/es unknown
- 2017-09-14 CN CN201780054555.6A patent/CN109689091A/zh active Pending
- 2017-09-14 ES ES17769027T patent/ES2824525T3/es active Active
- 2017-09-15 TW TW106131855A patent/TWI742158B/zh active
-
2019
- 2019-02-08 PH PH12019500280A patent/PH12019500280A1/en unknown
- 2019-03-14 ZA ZA2019/01597A patent/ZA201901597B/en unknown
-
2020
- 2020-08-13 US US16/947,694 patent/US11365222B2/en active Active
- 2020-09-14 HR HRP20201458TT patent/HRP20201458T1/hr unknown
- 2020-10-09 CY CY20201100952T patent/CY1124518T1/el unknown
- 2020-11-13 AU AU2020267278A patent/AU2020267278B2/en not_active Expired - Fee Related
-
2022
- 2022-06-08 US US17/805,873 patent/US11820796B2/en active Active
- 2022-11-14 JP JP2022181566A patent/JP2023011941A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46230B1 (fr) | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère | |
MA41717A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers | |
MA40794A1 (fr) | Nouveaux peptides et combinaisons de peptides et d'échafaudages destinés à être utilisés en immunothérapie contre le carcinome hépatocellulaire (chc) et d'autres cancers | |
CL2021002742A1 (es) | Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de francisella tularensis; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
CL2017002345A1 (es) | Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr | |
PH12020500025A1 (en) | Trimer stabilizing hiv envelope protein mutations | |
MA42021A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers | |
MA43618A1 (fr) | Nouveaux peptides, association de peptides en tant que cibles et destinés à être utilisés en immunothérapie contre le cancer de la vésicule biliaire et le cholangiocarcinome et autres cancers | |
MA42020A1 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
WO2017058892A3 (fr) | Procédés et compositions pour vecteurs viraux évitant les anticorps | |
MX2018012268A (es) | Receptores de celulas t. | |
MX2018012265A (es) | Receptores de celulas t. | |
MA42072A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers | |
TNSN08064A1 (en) | Albumin fusion proteins | |
PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
MA43477A1 (fr) | Immunothérapie contre le mélanome et d'autres cancers | |
Martellini et al. | HIV-1 enhancing effect of prostatic acid phosphatase peptides is reduced in human seminal plasma | |
EA200401504A1 (ru) | Слитый белок из числа регуляторных/вспомогательных белков вич | |
PE20191614A1 (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo | |
EA202191208A1 (ru) | ВЕКТОРЫ, СОДЕРЖАЩИЕ AIMP2-DX2 И ЦЕЛЕВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ ДЛЯ miR-142, И ИХ ПРИМЕНЕНИЕ | |
MA43482A1 (fr) | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers | |
MA56142A1 (fr) | Protéine modifiée séparée vp1 de capside de aav5 | |
MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
MX2023007319A (es) | Vacunas de acido nucleico. | |
EA202090326A1 (ru) | Стабилизирующие тример мутации белка оболочки hiv |